Articles tagged with Lung Tumors
Researchers have developed a new diagnostic method called spectral histopathology that facilitates marker-free detection of individual subtypes of lung cancers. The accuracy of this method is higher than traditional histopathology, reaching over 92%, allowing for more precise diagnosis and personalized treatment options.
Researchers at Houston Methodist have developed a new, ex vivo lung cancer model that mimics the process of tumor progression. The '4-D' model allows for the study of cancer metastasis, including the growth of primary tumors and formation of circulating tumor cells, providing insights into tumor progression and potential new therapies.
Researchers have developed nanocarriers that selectively release drugs in lung tumor areas, improving treatment efficacy by 10-25 times compared to traditional methods. This approach also reduces the total dose of medicines, minimizing undesirable effects.
Northeastern researchers have found that supplemental oxygenation can shrink tumors and improve cancer immunotherapy by inhibiting hypoxia-driven adenosine accumulation and weakening immunosuppression. This approach has the potential to increase survival rates of patients with cancer, which kills over 8 million people annually.
A study found that circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer can detect EGFR mutations, which are associated with expected patient outcomes. The presence of these mutations in cfDNA was linked to shorter overall survival and reduced disease progression-free survival.
Researchers used targeted NGS to identify genetic alterations in genes involved in DNA repair, cell survival, and proliferation pathways. The study found that accumulated mutations correlate with tumor progression and decreased survival rates in patients with advanced malignant lung cancer. The results highlight the potential of NGS to...
A new study published in the Journal of Clinical Investigation found that tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. These cells produce molecules promoting inflammation, and their role is crucial for bolstering anti-tumor immune responses.
Research reveals that minimally invasive adenocarcinoma (MIA) and adenocarcinoma in-situ (AIS) lung cancer patients have comparable five-year disease-free and overall survival rates of 97.7%. This finding suggests that tumor sub-classification may not provide additional prognostic information for patients with tumors ≤3 cm in size.
A 10-year analysis of data from an institutional patient registry indicates that 79% of tumors are controlled locally for early stage lung cancer patients treated with SBRT. The treatment resulted in minimal toxicity, with no grade 4 or 5 events recorded.
Analysis of over 600 small cell lung cancer and neuroendocrine tumors identified common molecular markers, including EGFR amplification, that could reveal new therapeutic targets. The study found notable differences in biomarker expression between SCLC and NET tumors.
A study published in Science found that sequencing a single region of a localized tumor can identify most cancer-driving genomic aberrations. The researchers identified 20 known cancer gene mutations across all regions of the same tumor, suggesting a potential connection to relapse.
Researchers identify RET M918T mutation in SCLC tumors, which drives increased ERK signaling and MYC expression. The mutation makes cells sensitive to tyrosine kinase inhibitors ponatinib and vandetanib.
Researchers have uncovered mutations in a cell-signaling pathway that plays a role in forming tumors. These genetic changes may expand treatments for patients, as drugs targeting some of these pathways are already available or in clinical trials.
Research found that low doses of arsenic, similar to those consumed by humans, cause lung cancer in male mice. Arsenic levels above 50 ppb led to significant increases in benign and malignant lung tumors.
Researchers develop device that spots lung cancer in exhaled breath, combining novel technologies for early detection and diagnosis. The breathalyzer test uses a nanotech chip to detect unique chemical signatures of lung cancer tumors, accurately distinguishing between benign and malignant lesions.
A new liquid biopsy test uses circulating tumour cells in blood samples to monitor and predict lung cancer response to treatment. The test has the potential to provide personalised medicine for the disease, particularly for small cell lung cancer with poor survival rates.
A study by Memorial Sloan Kettering Cancer Center found that genomic tumor testing can improve survival for patients with advanced lung cancers. The test identified oncogenic drivers in 64% of tumors, leading to improved outcomes when matched with targeted therapies.
Researchers have discovered that some lung cancers with EGFR gene mutations are uniformly treated throughout the tumor, while others have variable mutation presence. This finding has significant implications for diagnostic accuracy and precision medicine in lung adenocarcinoma.
Immunotherapy has shown huge potential in treating lung cancer by preventing tumour cells from escaping the immune system. New data on immunocheckpoint regulators such as PD-1 and PD-L1 have resulted in impressive global overall response rates of 20% to 25%.
Researchers have developed a novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) using quantitative (q)RT-PCR. The assay overcomes limitations of existing methods, including cost and interpretation challenges, with high sensitivity and ease of use.
Researchers found that targeting molecular profiles of non-small-cell lung cancer with mutated cancer-causing protein KRas is the most effective treatment strategy. The study suggests that combination therapy using approved inhibitors might improve outcomes for patients with wild-type KRas tumors.
A study led by UT Southwestern Medical Center researchers found that total tumor measurements greater than 3 inches predict shorter survival times in advanced lung cancer patients. Patients with larger tumors live an average of 9.5 months, compared to 12.6 months for those with smaller tumors.
Researchers found that a specific pattern in tumor pathology is strongly associated with cancer recurrence. Patients with this pattern are more likely to benefit from lobectomy and have a 75% lower risk of recurrence. The study may lead to new technology to precisely identify tumors with this pattern before surgery.
Researchers at Moffitt Cancer Center discovered a gene expression signature that may lead to new immune therapies for lung cancer patients. High levels of NF-κB in lung cancer tumors can act as a suppressor, boosting the immune system to eliminate cancerous cells.
Scientists developed a histology expression predictor for common types of lung cancer using paraffin samples, achieving accuracy comparable to pathologists. The technology has potential applications in predicting responses to therapies and prognostication.
A retrospective study found that placing a stent within the aorta facilitated tumor removal and eliminated heart-lung bypass needs. Patients with non-small cell lung carcinomas and sarcomas benefited from this minimally invasive approach.
Researchers have successfully treated metastatic lung cancer using cryoablation, a minimally invasive procedure that uses frozen balls of ice to kill cancerous tumors. The treatment has shown promising results, with 100% effectiveness in killing tumors at three-month follow-up and prolonged survival for patients.
Fox Chase researchers have discovered that nearly 6% of non-smoker lung cancer tissue samples show signs of HPV triggering the tumors. The study suggests a potential link between HPV and lung cancer, with implications for treatment and prognosis.
Researchers found that phenformin, a derivative of metformin, decreased tumor size and increased survival in mice with advanced stage lung tumors lacking LKB1 gene. Early treatment with phenformin causes slower tumor progression and increased survival for patients with non-small cell lung cancer.
Researchers compared the patterns of failure between stereotactic body radiotherapy (SBRT), lobectomy, and pneumonectomy for patients with stage I non-small-cell lung cancer. The results show comparable patterns of failure, but highlight the challenges in making such comparisons due to differences in patient and tumor-related factors.
A recent study found that tumor boards have a modest association with the types of treatments patients receive for certain cancers. For example, lung cancer and prostate cancer patients were more likely to receive higher-quality care when treated at hospitals with tumor boards. However, other types of cancer care remained unaffected by...
Lung cancer researchers at St. Joseph's Hospital and Medical Center identified a gene involved in non-small cell lung cancer tumor growth, leading to potential new treatments that inhibit tumor growth. The study found that the Fn14 gene is elevated in NSCLC tumors and promotes migration and invasion.
Researchers at Thomas Jefferson University have developed a new real-time tracking technique that can better predict and track tumor motion during radiotherapy, sparing healthy tissue. The technique has shown to deliver higher levels of radiation to moving tumors while reducing dose to critical organs.
Researchers found that targeting CD22 protein on lung cancer cells reduces tumor growth and metastasis in mouse models, leading to improved survival rates. The discovery may lead to the development of a novel therapy for non-small cell lung cancer.
Researchers at Penn developed a new mouse model of pulmonary lymphangioleiomyomatosis (LAM), a debilitating lung disease, that replicates the pathologic features of human disease. The study suggests that two readily available drugs, an antibiotic and a statin, may help treat and reverse symptoms.
Crizotinib successfully shrinks tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer. The treatment showed a high overall response rate of 60% and improved median progression-free survival.
Researchers have identified how EPHA3 gene mutations may promote lung cancer. The study found that loss of the gene diminishes its tumor-suppressive effect, potentially sparking tumor growth. The findings suggest that therapies targeting a downstream pathway may be beneficial for tumors with mutant EPHA3.
Chronic obstructive pulmonary disease (COPD) increases lung cancer risk through a novel mechanism involving long-term oxygen depletion and HIF-2a tumor growth signaling. COPD-induced signals may be susceptible to prevention or treatment with VEGFR-2 and EGFR inhibitors.
A new technique called Deep Inspiration Breath Hold (DIBH) helps deliver the correct dose to the right place, sparing healthy tissue. The study found that treating patients during DIBH reduced the heart mean dose by 68% and lung radiation by 20-30%, offering a clinical benefit for breast cancer patients.
Researchers have identified potential biomarkers for personalized medicine in lung cancer, such as a test that predicts patient response to certain treatments. The findings suggest that these innovative approaches could lead to more effective treatment strategies for patients with lung cancer.
Researchers discovered that manipulating two biochemical signals regulating mitochondria in cells can shrink human lung cancers in mice. By boosting fusion signal or blocking fission, they reduced cell division and increased cell death.
Researchers at Massachusetts General Hospital have defined a new genetic subtype of lung cancer driven by ROS1 gene rearrangements. Crizotinib treatment has shown promising results in controlling tumors in patients with this subtype, offering a new therapeutic option.
Researchers have identified protein signatures in mouse blood samples that reflect lung cancer biology in humans, paving the way for better monitoring of tumor progression and potential early detection strategies. The study's findings also suggest that these signatures may be useful in detecting lung cancer at an earlier stage.
A study of nearly 100 studies supports thermal ablation as a successful alternative to surgery and radiation therapy for patients with advanced lung cancer. The procedure has achieved an overall survival rate of 48-80 percent at two years, offering a safe and effective treatment option.
Research reveals that lung adenocarcinomas in never-smokers exhibit greater genome instability and altered genetic patterns compared to those in smokers. The findings suggest distinct molecular mechanisms driving the development of lung cancer in never-smokers, potentially requiring unique treatments.
A group of radiologists and biochemists have developed a new approach to improve the accuracy and reliability of medical imaging. By creating standardized benchmarks and calibration objects, they aim to provide hard numbers that can be used to justify treatments and accelerate cancer treatment approvals.
Researchers at MIT have identified a genetic change that helps lung tumors metastasize, with reduced NKX2-1 activity associated with higher death rates for lung-cancer patients. Understanding this gene's role may help scientists develop drugs to counteract its loss.
A new test identifying aggressive lung cancer sub-type in never-smokers may help doctors select the most appropriate therapies. The study found that tumors expressing a protein product called anaplastic lymphoma kinase (ALK) are more common in this group, increasing disease progression risk.
Researchers identified six gene markers in early-stage non-small cell lung cancer that can predict tumor relapse and survival rates. The six-gene classifier stratifies patients into low-, intermediate- and high-risk groups with significantly different relapse rates.
Researchers at Georgetown Lombardi Comprehensive Cancer Center found that robotic radiosurgery improved symptoms in patients with hilar lung tumors, reducing pain and improving breathing. However, the treatment did not show a significant impact on overall survival rates.
A new study published in the New England Journal of Medicine found that crizotinib caused tumors to stop growing, shrink or disappear in 57-33 percent of patients with a specific genetic mutation. This represents a significant improvement over the current standard treatment, which has a response rate of around 15 percent.
A study found that tumor budding is a distinct morphologic feature with biologic and prognostic significance in lung adenocarcinoma, significantly linked to aggressive disease characteristics. The presence of tumor budding was also associated with lower five-year survival rates.
Researchers at Stanford University have developed a new technique that triples the speed of MRI imaging, allowing for real-time tracking of moving lung tumors. This could lead to more effective radiation therapy and improved patient outcomes.
Cancer stem cells have been identified in a model of human lung cancer, but their uniqueness varies between tumors depending on the tumor's genetic signature. The study suggests that targeting specific cancer cell populations based on the tumor genotype may lead to personalized and effective treatments.
A recent study uses genomic analysis to understand complex cellular signals driving lung cancer's deadly spread. The research identifies specific molecules linked to non-small cell lung cancer's (NSCLC) invasive and metastatic processes, providing a basis for effective therapies.
UT Southwestern Medical Center is part of a nationwide study offering free genetic testing for lung cancer patients. The study aims to identify mutations in malignant lung tumors and develop targeted therapies. Participants will have access to their test results and guidance on potential clinical trials.
Researchers used FDG PET scans to identify 'cold spots' in tumors, finding that most were composed of dead cells. By reducing radiation doses to these areas, patients may experience less damage while achieving the same therapeutic effect.
A new vaccine has been proven safe and effective in treating mesothelioma, a rare cancer associated with asbestos exposure. The vaccine uses the patient's own dendritic cells to induce a T-cell response against mesothelioma tumors.
Researchers have discovered that lung cancer tumors alter the odor of bodily fluids, allowing for early detection through trained animal sensors and chemical analysis. The findings hold promise for improving diagnostic and prognostic approaches to lung cancer treatment.
Researchers identify a potential molecular mechanism by which NNK promotes lung tumor formation and development through DNMT1 accumulation. Accumulation of DNMT1 in lung adenomas from NNK-treated mice and tumors from lung cancer patients correlated with poor prognosis, suggesting an important link between tobacco smoking and lung cancer.